This trial is completed!
Search for a recruiting clinical trial for your condition
Your journey
1What's a trial
4Get in touch
More info
You can access this
clinical trial
if you have
and you are
between 18 and 55
years old
The phase for this study is not defined.
Show me locations

The purpose

The purpose of this study is to test the effects of nicotine on cognition with the following schizophrenia endophenotypes: prepulse inhibition, antisaccades, the continuous performance test, spatial working memory and a verbal memory task. Schizophrenia patients, unaffected first-degree relatives of schizophrenia patients and healthy controls receive transdermal nicotine in a double-blind, placebo-controlled, crossover study.

Provided treatments

  • Drug: Transdermal nicotine patch
  • Drug: Placebo patch

Locations near you

Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Tris trial is registered with FDA with number: NCT01315002. The sponsor of the trial is University Hospital, Bonn and it is looking for 121 volunteers for the current phase.
Official trial title:
Nicotine Effects on Endophenotypes of Schizophrenia